1. Home
  2. LXEH vs CDT Comparison

LXEH vs CDT Comparison

Compare LXEH & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixiang Education Holding Co. Ltd.

LXEH

Lixiang Education Holding Co. Ltd.

HOLD

Current Price

$1.40

Market Cap

2.7M

Sector

Real Estate

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$0.49

Market Cap

2.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXEH
CDT
Founded
2001
2019
Country
China
United States
Employees
N/A
4
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
2.4M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
LXEH
CDT
Price
$1.40
$0.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
395.1K
12.2M
Earning Date
05-01-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.37
52 Week High
$3.28
$11.00

Technical Indicators

Market Signals
Indicator
LXEH
CDT
Relative Strength Index (RSI) 52.64 35.84
Support Level $0.21 N/A
Resistance Level $1.68 $0.73
Average True Range (ATR) 0.15 0.23
MACD -0.01 0.01
Stochastic Oscillator 36.37 1.87

Price Performance

Historical Comparison
LXEH
CDT

About LXEH Lixiang Education Holding Co. Ltd.

Lixiang Education Holding Co Ltd is engaged in providing education services, including high school and vocational education services. It offers private basic education at the primary and junior high school levels. The Group has two reportable segments for operations, including high school and vocational education.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.

Share on Social Networks: